Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...
Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...
Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have improved in recent years ...
A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.
Acute myeloid leukemia (AML) is one of the most challenging blood cancers. The disease moves quickly and needs aggressive treatment with chemotherapy, sometimes followed by a bone marrow transplant.
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...
An all-oral combination of decitabine-cedazuridine (Inqovi) plus venetoclax (Venclexta) was active and safe in older or unfit acute myeloid leukemia (AML) patients deemed ineligible for intensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback